After Pfizer spent $1 billion upfront to license a targeted protein degrader from Arvinas, the latest clinical results suggest that the drug overall is no better than similar pills called SERDs. Arvinas said on Saturday …
- Roche reports long-term capabilities of multiple sclerosis drug May 30, 2025
- New technology could enhance CAR T therapy manufacture May 29, 2025
- New Eli Lilly acquisition to progress potential next-generation pain treatment May 28, 2025
- CHMP meeting highlights – May 2025 May 27, 2025
- Major trial indicates potential of novel hypertension drug May 26, 2025
- FDA approval marks shift in diabetic retinopathy treatment May 23, 2025
- FDA Approves Bio-Thera and Hikma’s Ustekinumab Biosimilar May 29, 2025
- FDA Approves BLA for Novavax’s COVID-19 Vaccine May 23, 2025
- Biogen Files Suit Against Neurimmune Over Rights to Bispecific Antibody May 21, 2025
- HyClone Seeks to Quash Amgen’s Subpoena Issued in Amgen/Accord Denosumab BPCIA Litigation May 21, 2025
- Regeneron Awarded $407 Million in Amgen Antitrust Suit May 19, 2025
- Three Ways GoodRx Is Helping Pharmacies Increase Profitability and Drive Innovation May 30, 2025
- Drug Channels News Roundup, May 2025: MFN Controversy, Plan Sponsors ♥️ Rebates, PBM Profits, and Fun in Congress May 28, 2025
- How the IRA’s Part B Coinsurance Inflation Adjustments Can Raise Seniors’ Drug Costs May 21, 2025
- What’s Next for Retail Pharmacy: Data, Debate, and Disruption (NEW Live Video Webinar) May 20, 2025
- Resetting the Walk-Away Price: How GoodRx Data Reveals New Realities of Prescription Abandonment May 16, 2025
- How Large PBMs Make Money Today: A 2025 Drug Channels Update May 13, 2025
- From Barriers to Bridges: Rethinking Medication Access for 2025 May 9, 2025